Abstract

Expanded Pilot and Feasibility Program The purpose of the Expanded Pilot and Feasibility Program (ePFP) of the Washington University Diabetes Research Center (DRC) is to extend our Pilot and Feasibility Program to diabetes investigators at institutions without NIDDK-supported Diabetes Research Centers. In this application, we propose to establish subcontracts with the University of Kentucky, the University of Utah, and the University of Wisconsin-Madison, three universities with outstanding research bases in diabetes. Philip Kern, Simon Fisher, and Alan Attie are internationally recognized diabetes researchers with strong records of leadership, who will serve as subcontract Program Directors at Kentucky, Utah, and Madison, respectively. Each subcontract will fund two meritorious pilot grants per year at each institution, and the program will be well integrated with the successful Pilot and Feasibility Program at Washington University. The ePFP leverages the success and experience of the Washington University DRC to serve a wider scientific community and enhances scientific interchange between investigators at the four institutions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK020579-44
Application #
10075917
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
44
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130

  Publications

Evans, Trent D; Jeong, Se-Jin; Zhang, Xiangyu et al. (2018) TFEB and trehalose drive the macrophage autophagy-lysosome system to protect against atherosclerosis. Autophagy 14:724-726
Lin, Meei-Hua; Miller, Joseph B; Kikkawa, Yamato et al. (2018) Laminin-521 Protein Therapy for Glomerular Basement Membrane and Podocyte Abnormalities in a Model of Pierson Syndrome. J Am Soc Nephrol 29:1426-1436
Sidhu, Rohini; Mikulka, Christina R; Fujiwara, Hideji et al. (2018) A HILIC-MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum. Biomed Chromatogr 32:e4235
Liu, Hui; Jin, Hongjun; Han, Junbin et al. (2018) Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques. Mol Imaging Biol 20:448-456
Wang, Songyan; Oestricker, Lauren Z; Wallendorf, Michael J et al. (2018) Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. PLoS One 13:e0192441
Turk, John; White, Tayleur D; Nelson, Alexander J et al. (2018) iPLA2? and its role in male fertility, neurological disorders, metabolic disorders, and inflammation. Biochim Biophys Acta Mol Cell Biol Lipids :
Chondronikola, Maria; Magkos, Faidon; Yoshino, Jun et al. (2018) Effect of Progressive Weight Loss on Lactate Metabolism: A Randomized Controlled Trial. Obesity (Silver Spring) 26:683-688
Higgins, Cassandra B; Zhang, Yiming; Mayer, Allyson L et al. (2018) Hepatocyte ALOXE3 is induced during adaptive fasting and enhances insulin sensitivity by activating hepatic PPAR?. JCI Insight 3:
Cahill, Alison G; Haire-Joshu, Debra; Cade, W Todd et al. (2018) Weight Control Program and Gestational Weight Gain in Disadvantaged Women with Overweight or Obesity: A Randomized Clinical Trial. Obesity (Silver Spring) 26:485-491
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97:1284-1298.e7

Showing the most recent 10 out of 654 publications